Reuters logo
8 months ago
BRIEF-Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ovarian cancer
December 12, 2016 / 9:11 PM / 8 months ago

BRIEF-Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ovarian cancer

Dec 12 (Reuters) - Novocure Ltd

* Novocure - topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of ttfields in recurrent ovarian cancer

* Novocure presents phase 2 pilot innovate trial results suggesting tumor treating fields plus paclitaxel may be safe as first-line treatment and may improve survival of patients with recurrent ovarian cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below